Ultralife Corporation Reports Third Quarter Results

Rhea-AI Summary

Ultralife Corporation reports Q3 2023 results with sales of $39.5 million, a 18.8% YoY increase. Operating income of $2.1 million, compared to a loss of $0.6 million in Q3 2022. Adjusted EPS of $0.10, compared to a loss of $0.03 in Q3 2022. Adjusted EBITDA of $3.5 million, a 177.3% YoY increase. Backlog of $101.1 million.

Positive

• Ultralife Corporation reports strong sales growth in Q3 2023 with a 18.8% YoY increase. Adjusted EBITDA also shows significant improvement with a 177.3% YoY increase. The company has a backlog of $101.1 million, indicating a strong demand for its products.

Negative

• None.

NEWARK, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2023 with the following highlights:

• Sales of $39.5 million representing an 18.8% year-over-year increase
• Operating income of $2.1 million versus a loss of $0.6 million for the 2022 third quarter
• Adjusted EPS of $0.10 compared to a loss of $0.03 for the 2022 third quarter
• Adjusted EBITDA of $3.5 million representing a 177.3% year-over-year increase
• Backlog of $101.1 million exiting the 2023 third quarter
  

“Driven by continuing strong demand from our government/defense and medical customers, sales grew 19% for both the 2023 third quarter and the first nine months to $39.5 million and $114.1 million, respectively, over the prior year periods. We continue to focus on recapturing gross margin through price realization, lean manufacturing initiatives and level-loaded production, which resulted in a year-over-year improvement in gross margin of 460 basis points to 24.8% for the third quarter. On the strength of higher sales, gross margin improvement and disciplined spending, operating profit of $2.1 million far exceeded the operating loss of $0.6 million from the year-earlier quarter. Finally, our efforts to strengthen our relationships with key customers using our global new product development resources are bearing fruit as we continue to sustain our backlog in excess of $100 million,” said Mike Manna, President and Chief Executive Officer. “As we close out 2023 with a strong backlog, we are well positioned to continue our profitable growth and to generate incremental cashflow to reduce our acquisition debt and further invest in our businesses, including new product development, strategic capital expenditures and accretive acquisitions.”

Third Quarter 2023 Financial Results

Revenue was $39.5 million, an increase of $6.3 million, or 18.8%, as compared to revenue of $33.2 million for the third quarter of 2022. Overall, government/defense sales increased 48.1% and commercial sales increased 5.6% over the 2022 period. Battery & Energy Products sales increased 11.7% to $31.9 million compared to $28.6 million last year, reflecting increases of 36.2% in government/defense sales and 37.9% in medical battery sales, partially offset by decreases of 1.8% in oil & gas market sales and 14.9% in other commercial sales. Communications Systems sales increased by 62.7% to $7.6 million compared to $4.7 million for the same period last year, primarily attributable to shipments of vehicle-amplifier adaptors to a global defense contractor for the U.S. Army and of integrated systems of amplifiers and radio vehicle mounts to a major international defense contractor under an ongoing allied country government/defense modernization program. Our total backlog exiting the 2023 third quarter was $101.1 million with over $35 million of the total backlog due to ship over the remaining three months of 2023.

Gross profit was $9.8 million, or 24.8% of revenue, compared to $6.7 million, or 20.2% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 24.2%, compared to 18.7% last year, primarily due to more efficiencies and higher cost absorption resulting from a concerted effort to level-load production more evenly across the 2023 quarter, as well as improved price realization. Communications Systems gross margin was 27.0% compared to 29.5% last year, primarily due to inefficiencies caused by component delays from suppliers, partially offset by higher factory volume.

Operating expenses were $7.6 million, compared to $7.3 million for the 2022 third quarter. Operating expenses were 19.3% of revenue compared to 22.0% of revenue for the year-earlier period.

The combination of higher gross profit and leveraging of operating expenses resulted in a $2.7 million increase in operating income to $2.1 million from an operating loss of $0.6 million last year.

Net income was $1.3 million or $0.08 per diluted share on a GAAP basis, compared to a net loss of $0.2 million or $0.01 per diluted share for the third quarter of 2022. Adjusted EPS was $0.10 on a diluted basis for the third quarter of 2023, compared to a loss of $0.03 for the 2022 period. Adjusted EPS excludes the provision for deferred taxes of $0.4 million which primarily represents non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $3.5 million for the third quarter of 2023, or 8.8% of sales, compared to $1.3 million, or 3.8% of sales, for the year-earlier period.

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EPS to EPS and adjusted EBITDA to net income attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

Conference Call Information

Ultralife will hold its third quarter earnings conference call today at 8:30 AM ET.

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: https://register.vevent.com/register/BI7f14d2264d2242c1adb217d21d75ab21. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include the impact of COVID-19 and related supply chain disruptions, potential reductions in revenues from key customers, acceptance of our new products on a global basis and uncertain global economic conditions. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (Dollars in Thousands)
(Unaudited)
ASSETS
		September 30, 2023							December 31, 2022
Current Assets:
Cash		$9,301							$5,713
Trade Accounts Receivable, Net			27,189							27,779
Inventories, Net			46,634							41,192
Prepaid Expenses and Other Current Assets			6,429							4,304
Total Current Assets			89,553							78,988
Property, Plant and Equipment, Net			21,166							21,716
Goodwill			37,357							37,428
Other Intangible Assets, Net			15,270							15,921
Deferred Income Taxes, Net			10,728							12,069
Other Non-Current Assets			2,035							2,308
Total Assets		$176,109							$168,430
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts Payable		$13,470							$16,074
Current Portion of Long-Term Debt			2,000							2,000
Accrued Compensation and Related Benefits			2,467							2,890
Accrued Expenses and Other Current Liabilities			8,449							7,949
Total Current Liabilities			26,386							28,913
Long-Term Debt, Net			24,108							19,310
Deferred Income Taxes			1,825							1,917
Other Non-Current Liabilities			2,032							1,887
Total Liabilities			54,351							52,027
Shareholders' Equity:
Common Stock			2,075							2,057
Capital in Excess of Par Value			188,852							187,405
Accumulated Deficit			(43,627)							(47,951)
Accumulated Other Comprehensive Loss			(4,176)							(3,750)
Treasury Stock			(21,484)							(21,484)
Total Ultralife Equity			121,640							116,277
Non-Controlling Interest			118							126
Total Shareholders’ Equity			121,758							116,403
Total Liabilities and Shareholders' Equity		$176,109							$168,430

                                                                        

ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In Thousands Except Per Share Amounts)
(Unaudited)
	Three-Month Period Ended								Nine-Month Period Ended
	September  30,				September 30,				September 30,				September  30,
		2023				2022				2023				2022
Revenues:
Battery & Energy Products	$31,919				$28,583				$94,250				$87,873
Communications Systems		7,569				4,651				19,846				7,860
Total Revenues		39,488				33,234				114,096				95,733
Cost of Products Sold:
Battery & Energy Products		24,191				23,238				72,467				68,656
Communications Systems		5,523				3,281				13,831				5,758
Total Cost of Products Sold		29,714				26,519				86,298				74,414
Gross Profit		9,774				6,715				27,798				21,319
Operating Expenses:
Research and Development		1,869				1,896				5,679				5,425
Selling, General and Administrative		5,770				5,405				16,293				15,982
Total Operating Expenses		7,639				7,301				21,972				21,407
Operating Income (Loss)		2,135				(586)				5,826				(88)
Other Income (Expense)		(386)				254				178				22
Income (Loss) Before Income Taxes		1,749				(332)				6,004				(66)
Income Tax Provision (Benefit)		446				(90)				1,688				(171)
Net Income (Loss)		1,303				(242)				4,316				105
Net (Loss) Income Attributable to Non-Controlling Interest		(27)				(3)				(8)				-
Net Income (Loss) Attributable to Ultralife Corporation	$1,330					($239)			$4,324				$105
Net Income (Loss) Per Share Attributable to Ultralife Common Shareholders – Basic	$.08				($.01)				$.27				$.01
Net Income (Loss) Per Share Attributable to Ultralife Common Shareholders – Diluted	$.08				($.01)				$.27				$.01
Weighted Average Shares Outstanding – Basic		16,238				16,133				16,172				16,122
Weighted Average Shares Outstanding – Diluted		16,303				16,133				16,174				16,144

Non-GAAP Financial Measures

Adjusted EBITDA

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to U.S. Generally Accepted Accounting Principles (“GAAP”) financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

ULTRALIFE CORPORATION AND SUBSIDIARIES

CALCULATION OF ADJUSTED EBITDA

(Dollars in Thousands)

(Unaudited)

	Three-Month Period Ended				Nine-Month Period Ended
	September 30, 2023		September 30, 2022		September 30, 2023		September 30, 2022
Net Income (Loss) Attributable to Ultralife Corporation	$1,330		($239)		$4,324		$105
Adjustments:
Interest Expense, Net	586		272		1,450		583
Income Tax Provision (Benefit)	446		(90)		1,688		(171)
Depreciation Expense	760		815		2,282		2,450
Amortization Expense	227		318		663		969
Stock-Based Compensation Expense	131		179		424		552
Cyber-Insurance Policy Deductible	-		-		100		-
Non-Cash Purchase Accounting Adjustment	-		-		-		55
Adjusted EBITDA	$3,480		$1,255		$10,931		$4,543

Adjusted Earnings Per Share

In evaluating our business, we consider and use adjusted EPS, a non-GAAP financial measure, as a supplemental measure of our business performance. We define adjusted EPS as net income attributable to Ultralife Corporation excluding the provision (benefit) for deferred income taxes divided by our weighted average shares outstanding on both a basic and diluted basis. We believe that this information is useful in providing period-to-period comparisons of our results by reflecting the portion of our tax provision that we expect will be predominantly offset by our U.S. net operating loss carryforwards and other tax credits for the foreseeable future. We reconcile adjusted EPS to EPS, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EPS as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EPS to EPS and net income attributable to Ultralife Corporation.

ULTRALIFE CORPORATION AND SUBSIDIARIES

CALCULATION OF ADJUSTED EPS

(In Thousands Except Per Share Amounts)

(Unaudited)

	Three-Month Period Ended
	September 30, 2023						September 30, 2022
	Amount		Per Basic Share		Per Diluted Share		Amount		Per Basic Share		Per Diluted Share
Net Income (Loss)	$1,330		$.08		$.08		($239)		($.01)		($.01)
Attributable to Ultralife Corporation
Deferred Tax Provision (Benefit)	357		.02		.02		( 308)		(.02)		(.02)
Adjusted Net Income (Loss)	$1,687		$.10		$.10		($547)		($.03)		($.03)
Weighted Average Shares Outstanding			16,238		16,303				16,133		16,133

	Nine-Month Period Ended
	September 30, 2023						September 30, 2022
	Amount		Per Basic Share		Per Diluted Share		Amount		Per Basic Share		Per Diluted Share
Net Income Attributable to Ultralife Corporation	$4,324		$.27		$.27		$105		$.01		$.01
Deferred Tax Provision (Benefit)	1,245		.07		.07		(683)		(.05)		(.05)
Adjusted Net Income (Loss)	$5,569		$.34		$.34		($578)		($.04)		($.04)
Weighted Average Shares Outstanding			16,172		16,174				16,122		16,144

Company Contact:	Investor Relations Contact:
Ultralife Corporation	LHA
Philip A. Fain	Jody Burfening
(315) 210-6110	(212) 838-3777
pfain@ulbi.com	jburfening@lhai.com

FAQ

What are the key financial results of Ultralife Corporation in Q3 2023?

Ultralife Corporation reported sales of $39.5 million, operating income of $2.1 million, adjusted EPS of $0.10, and adjusted EBITDA of $3.5 million in Q3 2023.

How does the sales growth in Q3 2023 compare to the previous year?

Sales in Q3 2023 increased by 18.8% compared to the same period in the previous year.

What is the backlog of Ultralife Corporation?

Ultralife Corporation has a backlog of $101.1 million as of the end of Q3 2023.